4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
9.66
+1.34 (16.11%)
At close: Oct 8, 2025, 4:00 PM EDT
9.74
+0.08 (0.83%)
After-hours: Oct 8, 2025, 7:47 PM EDT
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $15.00K in the quarter ending June 30, 2025, with 200.00% growth. This brings the company's revenue in the last twelve months to $33.00K, down -99.84% year-over-year. In the year 2024, 4D Molecular Therapeutics had annual revenue of $37.00K, down -99.82%.
Revenue (ttm)
$33.00K
Revenue Growth
-99.84%
P/S Ratio
13,671.09
Revenue / Employee
$145
Employees
227
Market Cap
451.15M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 37.00K | -20.69M | -99.82% |
Dec 31, 2023 | 20.72M | 17.59M | 562.29% |
Dec 31, 2022 | 3.13M | -14.91M | -82.65% |
Dec 31, 2021 | 18.04M | 4.43M | 32.52% |
Dec 31, 2020 | 13.61M | 6.63M | 94.85% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
FDMT News
- 8 days ago - 4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors - Seeking Alpha
- 26 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - 4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness - GlobeNewsWire
- 6 weeks ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire
- 2 months ago - 4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 2 months ago - 4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study - Benzinga